Cheang and colleagues showed no added benefit in basal-like breast cancer but identified a substantial benefit in Her2-enriched high-risk breast cancer from the anthracycline-containing CEF chemotherapy as compared to CMF [7]. This evidence concerns the gene ERBB2 and breast carcinoma.